Global Blood Cancer & BMT Access Inequality Analysis

By abhishek.verma75000 · May 25, 2026

A comprehensive healthcare analytics study examining global disparities in Myeloma and Leukemia outcomes across 50 countries, with a focus on disease…

The analysis identified the top 10 countries where disease burden (based on myeloma and leukemia incidence rates) significantly outpaces BMT (Bone Marrow Transplant) access scores. Two visualizations were generated: a bar chart highlighting the gap magnitude for each country, and a scatter plot comparing all countries' burden scores against their BMT access scores — making it easy to spot which nations are most underserved relative to their disease load.

The grouped bar chart compares average 5-year survival rates for myeloma and leukemia across continents. The visualization clearly shows how each continent performs for both cancer types side by side, making it easy to spot regional differences and which cancer type has better survival outcomes in each region.

Northern Europe has the highest overall blood cancer incidence rate, with a combined myeloma and leukemia rate of 23.05 per 100K. Two grouped bar charts and supporting data tables were generated to visualize these regional differences clearly.

Yes — higher hematologist density strongly correlates with better survival outcomes. Countries with more hematologists per million population consistently show significantly higher 5-year survival rates for both myeloma and leukemia. Two scatter plots with trend lines illustrate this relationship clearly.

The analysis identified the top 10 countries with the highest combined myeloma and leukemia new cases. A stacked bar chart was generated showing each country's breakdown between myeloma and leukemia cases, making it easy to compare both the total burden and the relative contribution of each cancer type across countries.

The analysis identified the countries with the highest death-to-new-case ratios for both leukemia and myeloma. Two bar charts were generated showing the top 10 countries for each cancer type, along with data tables for detailed comparison. A higher ratio indicates that for every new case diagnosed, a greater proportion of patients are dying — which can reflect differences in healthcare access, treatment quality, or late-stage diagnosis rates.

All 50 countries were ranked by a composite Treatment Effectiveness Score combining normalized Myeloma and Leukemia 5-year survival rates. A grouped horizontal bar chart was generated comparing the top 10 and bottom 10 countries side-by-side, also showing their BMT Access Scores and Hematologists per Million (scaled x10) for direct comparison. The results reveal a striking alignment between high survival rates and superior healthcare resources.

The analysis successfully identified outlier countries across three key metrics — BMT Centers, Hematologists Per Million, and BMT Access Score — using the IQR 1.5x rule. A box plot was generated showing the distribution of each metric with outlier points highlighted, and a summary table was created listing the outlier countries along with their actual values versus the expected range.

Two visualizations were successfully generated to break down the global cancer burden by continent. The first chart (stacked bar) shows the total new cases for Myeloma and Leukemia side by side per continent, making it easy to see which regions contribute the most to global case volumes. The second chart (grouped bar) displays the Case-Fatality Ratio (CFR = Deaths / New Cases) for both cancers per continent, highlighting where mortality is highest relative to case counts.

The correlation analysis reveals remarkably strong relationships between healthcare infrastructure metrics and patient outcomes. Two data tables were generated summarizing all pairwise correlations across the six key variables. The strongest positive correlation is between Myeloma 5-Year Survival and Leukemia 5-Year Survival (r = 0.993), indicating countries with better myeloma outcomes also tend to have better leukemia outcomes. BMT Access Score is nearly as strongly correlated with both survival metrics (r = 0.989 for Myeloma, r = 0.992 for Leukemia), confirming that transplant infrastructure is a critical driver of patient survival. Hematologists per Million also shows strong positive associations with survival (r = 0.926 for both cancers). On the negative side, higher incidence rates are associated with lower survival rates, with Leukemia Incidence negatively correlated with Leukemia Survival (r = -0.891) and Myeloma Incidence negatively correlated with Myeloma Survival (r = -0.885).